In this retrospective study, researchers assessed the turnaround time of mutational tests in patients with newly diagnosed acute myeloid leukemia (AML) and the time from diagnosis to treatment initiation....
Researchers examined the epidemiology of hydroxymethylbilane synthase (HMBS) gene defects and activity levels among patients with acute intermittent porphyria to better understand the role of HMBS activity...
Individuals with acute hepatic porphyria often experience acute attacks and chronic symptoms which greatly diminish their quality of life. Researchers examined the efficacy of givosiran in reducing these...
Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
Individuals with acute myeloid leukemia often have low levels of vitamin C and vitamin D at the time of diagnosis. Researchers examined how supplementation of these vitamins during treatment impacted...
Researchers reported on the treatment approaches and outcomes of patients with T‑cell prolymphocytic leukemia after allogeneic transplant in a multicenter, retrospective study.
